Frontline osimertinib significantly improved overall survival compared with erlotinib or gefitinib in patients with EGFR-positive local advanced or metastatic non–small cell lung cancer, according to results from the phase III FLAURA trial.
Original Article: Osimertinib Improves Survival in Frontline EGFR+ NSCLC